Results 181 to 190 of about 101,286 (277)

PD‐L1‐Inhibitor‐Associated Hidradenitis Suppurativa

Journal of Cutaneous Pathology, EarlyView.
Annie Jin, Katherine T. Steele, Emily Y. Chu   +2 more
wiley   +1 more source

Cutaneous Immune‐Related Adverse Events and Efficacy of Immune Checkpoint Inhibitors for Patients With Advanced Solid Organ Malignancies

International Journal of Dermatology, EarlyView.
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with advanced solid tumors. While low‐grade immune‐related adverse events (irAEs) are associated with prolonged survival, high‐grade irAEs have been associated with poorer survival. Cutaneous immune‐related adverse events (cirAEs) affect up to 20%
David O'Reilly, Gregg Murray, Orla M Fitzpatrick, Hebatalla Ismail, Gavin P Dowling, Gargi Roy, David Synnott, Maggie O'Connor, Bryan T Hennessy, Oscar Breathnach, Liam Grogan, Megan Greally, Adrian Murphy, Patrick G Morris, Karen Eustace, Muireann Roche, Stephen Madden, Jarushka Naidoo   +17 more
wiley   +1 more source

Nivolumab plus ipilimumab versus lenvatinib or sorafenib for US and Chinese patients with unresectable hepatocellular carcinoma: a cost-effectiveness analysis. [PDF]

Front Public Health
Wu Q, Qin Y, Li Q.
europepmc   +1 more source

A case of diverse psychiatric and functional impairments following immune checkpoint inhibitor therapy [PDF]

PCN Rep
Abstract Background Immune checkpoint inhibitors (ICIs) can cause a range of immune‐related adverse events (irAEs), including rare neuropsychiatric complications. However, these events often present with diverse and non‐specific symptoms, making diagnosis difficult.
Ikegami T, Sadahiro R, Yamaguchi J, Nishikawa E, Wada S, Terada T, Nakahara R, Matsuoka H.   +7 more
europepmc   +2 more sources

Exceptional therapeutic benefit of imatinib in cKIT‐mutated mucosal melanoma followed by a KIT mutation loss

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Hannah Zillikens, Corinna Scheib, Vicky Peller, Christina Müller, Sebastian Bauer, Ina Pretzell, Klaus Griewank, Antje Sucker, Eva Hadaschik, Felicitas Guntrum, Sven Holger Baum, Alexander Roesch, Selma Ugurel, Dirk Schadendorf, Lisa Zimmer, Elisabeth Livingstone   +15 more
wiley   +1 more source

Primary and Secondary Grzybowski’s Generalized Eruptive Keratoacanthoma: A New Perspective on Management, Clinical Features, and Prognosis

International Journal of Dermatology, EarlyView.
ABSTRACT Grzybowski's generalized eruptive keratoacanthoma (GEKA) is a rare variant of keratoacanthomas, characterized by hundreds to thousands of lesions, accompanied by pruritus, mucosal involvement, and comorbidities. Our aim was to analyze the clinical presentation, associated comorbidities, treatment strategies, and outcomes of GEKA.
Nicholas Florin Kormos, Carina Maria Petrenciu, Alin Stefan Vizitiu, Raluca Ghețe, Umer Nadir, Adrian Lucian Baican, Stanislav N. Tolkachjov   +6 more
wiley   +1 more source

Very Late Recurrence of Clear Cell Renal Cell Carcinoma With Pancreatic and Hepatic Metastases Showing Durable Response to Dual Checkpoint Blockade. [PDF]

Clin Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Immune Checkpoint Inhibitor-Related Hypophysitis and Pituitary Dysfunction: A Systematic Review of Diagnosis and Management. [PDF]

Cureus
SirDeshpande P, Hegde SBS, Akhtar H.
europepmc   +1 more source

The Hungry Cancer Patient: A Case of Money Ill Spent. [PDF]

, 2018
Zibelli, Allison
core   +1 more source

Oligoclonal B cell expansion and passenger fusion genes predict response to Nivolumab in recurrent ovarian cancer: phase II Kyoto trial. [PDF]

Cancer Immunol Immunother
Murakami R, Hamanishi J, Brown JB, Hosoe Y, Kobayashi T, Konishi T, Miyamoto T, Mizuno R, Taki M, Yamanoi K, Yamaguchi K, Mandai M.   +11 more
europepmc   +1 more source